Health & Fitness
Health and Fitness
Health and Fitness 
Tue, August 2, 2011
Allegiance';s ";CinGx&;#8482;"; and ";Relieva&;#8482;"; make inroads in the treatment of Type 3 Diabetes and Psoriasis
TORONTO, Aug. 2, 2011 /CNW/ - Allegiance Equity Corporation (TSXV:ANQ) developed CinGx™ and Relieva™ providing new and dramatic opportunities in the functional food and dermatology industries. Development of new nutritional ingredients such as pro biotics in Activia yogurt and polysterols in Becel increased sales, revenues, and shareholder value and by several hundred millions to several billions of dollars. Allegiance continues to create a network of worldwide renowned scientific, research, regulatory organizations and universities, manufacturers, scientists and suppliers as the basis to its active portfolio.
Allegiance in the past 90 days has completed two license agreements with extremely successful companies that have committed substantial financial and other resources to marketing both CinGx™ and Relieva™. These two licensees have combined sales of $275 million annually.
Agreement With Nealanders International to Market and Distribute CinGx™
Nealanders International - a world-class supplier of ingredients and additives in the food industry - has agreed to market and distribute CinGx™ in North America. CinGx™ is a revolutionary new product that helps prevent and treat Type 3 Diabetes. This proprietary food additive has a very compelling set of health benefits that enhance the value of most food and beverage products. Benefits include reducing blood sugar, cholesterol and triglycerides, while improving memory, cognitive function, energy and mental well-being.
Recent research discovered that the brain produces insulin and depriving brain cells of insulin damages the cells, leading to memory loss, dementia, and Alzheimer's disease. The impact of high blood glucose levels results in Type 3 Diabetes, also known as "brain diabetes." CinGx™ will greatly benefit the rapidly increasing number of North Americans diagnosed with diabetes, particularly Type 3 Diabetes.
CinGx™ captured the attention of leading research scientists including Dr. William Klein, Neurobiology Professor at North-western University, and Dr. Marcus Cantillon, American Board Certified Neurologist and Psychiatrist which marks an important Milestone for Allegiance.
"We're intrigued by the claim that insulin receptor protein tyrosine kinase might be stimulated by Allegiance's formulation," said Dr. Klein.
Dr. Marcus Cantillon invited Allegiance to speak at the CBI's 4th Annual Alzheimer's Drug Development Summit which was chaired by Dr. Cantillon. Both Klein and Cantillon acknowledge the need for safe alternative treatments for Type 3 diabetes. The Klein Lab at North-western University specializes in research on Type 3 Diabetes.
"Diabetes is one of the clear metabolic risk factors for Alzheimer's Disease (AD), perhaps through insulin signalling or secondary cardiovascular effects," says Dr. Cantillon, American Board Certified Neurologist and Psychiatrist. "After rosiglitazone and other failures, there are no metabolic treatments in sight for AD that are effective and/or do not have serious side effects. Therefore, insulin receptor protein tyrosine kinase treatment for Type 3 Diabetes might represent a new opportunity for long term safe prevention of AD."
"Nealanders is poised to market CinGx™ to its clients for placement in a variety of foods and beverages. Nealanders, the leading technology based ingredient company, has 2,000 customers in every corner of the industry, from nutrition, baking, confection, and food processing, to dairy, dry blending, pharmaceutical and more. They will maximize the commercialization of CinGx™ across a broad spectrum of mass market food products. Nealanders may not make the foods we eat but makes the foods we eat better," says David Solomon, President of Allegiance Equity.
ABOUT NEALANDERS
Nealanders is recognized as the leader in the manufacturing and distributing of food ingredients, specializing in antioxidants, release agents, dough conditioners and enrichment blends. Proudly Canadian, Nealanders' Head Office is located in Mississauga, ON, with facilities strategically located across North America providing their customers with coast-to-coast coverage in both distribution and technical sales. On the leading edge of emerging trends and a strategic focus on Wellness.
Nealanders has extensive laboratory capabilities for product development and full technical and regulatory support. Nealanders embraces a customer focused mindset and value creation for their customers.
"I am very excited about moving forward with this revolutionary new additive," says Steve Owen, VP Sourcing, Product Development & GM - Ontario. "With the added value CinGx™ brings to our customers' products and the important health benefits for consumers, everybody wins."
Agreement with Premier Selling Technologies Inc. to market and distribute Relieva
Prime Pharmaceutical Corporation (Prime) a subsidiary of Allegiance invented a patented extraction process which increases the concentration of the beneficial alkaloids from Mahonia Aquifolium by up to 75 times to create its proprietary extract Psorberine™.
Premier through its partner Yum Consumer Products (YCP) specializes in internet marketing via affiliate & direct Ad networks. YCP and its partner have generated over $500,000,000 in online product sales in the past 3 years.
Relieva™ is made with Psorberine™ an anti-inflammatory, antibacterial product for the treatment of psoriasis and atopic dermatitis. Relieva™ provides immediate relief for itching, irritation and inflammation associated with almost all problem skin conditions with zero toxicity and irritation.
Relieva™ is a premium skin care product for everyday use for healthy skin. However that is only half the story. Relieva™ and Psorberine™ have a number of significant distinct competitive advantages over existing psoriasis treatments including the world's largest selling psoriasis treatment. Other psoriasis treatments (including the leader) may lose their effectiveness over time as the disease builds up tolerability to other treatments this is not the case with Relieva™ that has a zero irritancy and toxicity rating, with no known health risks or side effects.
Prime is also in discussion with two multinationals for licensing Relieva™ one of which is one of the largest consumer goods companies in the world and the other a Spanish Pharmaceutical Company. These companies are in their initial stages of due diligence. Prime is also continuing to work with DSE Health Solutions LLC Edison, New Jersey.
"We are confident that Premier, will more than exceed the minimums that will result in Relieva™ becoming the market leader in on line sales." Prime developed a new formulation for Premier that is more effective and pleasing to use.
ABOUT ALLEGIANCE
Allegiance develops products for mass market opportunities having clearly identified product deficiencies and dissatisfied patients and consumers who suffer widespread diseases and conditions including diabetes, cholesterol, Alzheimer's and Dementia. Allegiance patents, regulatory approvals and licenses these technologies for royalties and licensing fees.
Interest of Management Notice of Intention to Distribute
Palm American Investments Inc is the controlling shareholder of Allegiance holding 2,014,331 common shares and is controlled by David Solomon, Marilyn Bloovol and members of their family.
Palm American Investment Inc. filed a Notice of Intention to sell up to 600,000 common shares on July 5th 2011 by way of private sale or on the market from time to time of which 400.000 have been sold in the market to date.
There are presently 7,061,921 common shares of Allegiance issued and outstanding, in addition Allegiance completed a private placement of 583,333 common shares on July 20th 2011.
Additional information relevant to the Company's activities, including the Company's press releases can found on SEDAR at [ www.sedar.com ] and [ www.allegianceequity.com ].
The TSX Venture Exchange has not reviewed and does not accept responsibility FOR THE ADEQUACY OR ACCURACY FOR HIS PRESS RELEASE, WHICH HAS BEEN PREPARED BY MANAGEMENT.